Default company panoramic image
Ba6e9b76 e2d6 46cd a851 bcb42e638c02

Hibernaid, Inc.

The only pharmacologically induced method to achieve Therapeutic Hypothermia.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Troy, NY, USA
  • Currency USD
  • Founded June 2012
  • Employees 5
  • Incorporation Type C-corp
  • Website hibernaid.com

Company Summary

BioPharma IND-ready to initiate Ph-1 study in patients at University of Pittsburgh. HBN-1 is only pharmacologic method to reduce & maintain core body temp which is Amer Heart Assoc recommended treatment for resuscitated post-cardiac arrest. Over $1M in Founder $ invested as well as $3M NIH award for preclin program. Multi-$B global mkt. Pt study yields efficacy to trigger exit in late 2019, or option to continue to add further value.

Team

  • Default avatar
    Laurence Katz, MD
    Chief Med Officer, co-founder

    Professor Emergency Med at Univ of NC, discovered HBN-1, acknowledged opinion leader in Therapeutic Hypothermia.

  • Bd24eb5b 8e65 43e4 93f2 f19d56547b82
    Director of Chemistry, Manufacturing and Control

    20+ years in the field, numerous successful drug development programs. 6 years with the company

  • 1d8f2c3b 34cf 4076 aed5 d9cb7da2321c
    Director, Medical/Scientific Writing, FDA document preparation

    30 yrs experience with Big Pharma, consulting and IND, NDA filings.

  • 90188534 2f08 4047 9008 9f337acfe7be
    Co-Founder, VP, Finance Admin and Systems Support

    15 yrs Big Pharma responsible for $30M+ Clinical budgets for a 200 person research department. Three prior successful start-ups

  • Default avatar
    Dr. Ronald Tribble
    Senior Business Advisor to CEO

    20 yrs in private dental practice, board participation and senior positions in various successful business ventures. Hibernaid investor.

Advisors

Previous Investors